PDC31

OC(C=C1)=CC=C1C[C@H](C(N[C@@H](C(O)=O)CCCCN)=O)NC([C@@H](CC(O)=O)NC([C@@H](CCCNC(N)=O)NC([C@H](NC(CNC([C@@H](CC(C)C)NC([C@H](N)[C@H](C)CC)=O)=O)=O)CC2=CN=CN2)=O)=O)=O

[1]Sharif NA, et al. Prostaglandin FP receptor antagonists: discovery, pharmacological characterization and therapeutic utility. Br J Pharmacol. 2019 Apr;176 (8) :1059-1078. |[2]Doheny HC, et al. THG113.31, a specific PGF2alpha receptor antagonist, induces human myometrial relaxation and BKCa channel activation. Reprod Biol Endocrinol. 2007 Mar 16;5:10. |[3]Friel AM, et al. Specific PGF (2alpha) receptor (FP) antagonism and human uterine contractility in vitro. BJOG. 2005 Aug;112 (8) :1034-42. |[4]Böttcher B, et al. A first-in-human study of PDC31 (prostaglandin F2α receptor inhibitor) in primary dysmenorrhea. Hum Reprod. 2014 Nov;29 (11) :2465-73.